Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
47.24
+1.22 (2.65%)
Nov 22, 2024, 4:00 PM EST - Market closed
Ultragenyx Pharmaceutical Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -558.99 | -606.64 | -707.42 | -454.03 | -186.57 | -402.73 | Upgrade
|
| Depreciation & Amortization | 34.68 | 26.01 | 18.22 | 13.24 | 12.26 | 8.54 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 75.03 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -16.09 | -13.24 | 22 | 48.67 | -169.56 | -19.63 | Upgrade
|
| Stock-Based Compensation | 151.61 | 135.23 | 130.38 | 104.95 | 85.74 | 82 | Upgrade
|
| Other Operating Activities | -34.28 | -1.06 | 21.09 | 11.71 | 21.24 | 3.76 | Upgrade
|
| Change in Accounts Receivable | -11.95 | -22.78 | -12.07 | -5.43 | 9.84 | -20.1 | Upgrade
|
| Change in Inventory | -10.71 | -6.93 | -9.7 | -3.12 | -1.35 | -4.45 | Upgrade
|
| Change in Accounts Payable | 19.21 | 2.38 | 87.44 | 32.31 | 26.85 | 13.31 | Upgrade
|
| Change in Unearned Revenue | -1.48 | -1.48 | -7.6 | -57.49 | 66.57 | - | Upgrade
|
| Change in Other Net Operating Assets | 11.01 | 15.33 | 3.8 | -29.51 | 2.75 | -8.22 | Upgrade
|
| Operating Cash Flow | -418.59 | -474.81 | -380.47 | -338.7 | -132.22 | -345.38 | Upgrade
|
| Capital Expenditures | -8.44 | -44.27 | -116.12 | -73.09 | -43.91 | -24.83 | Upgrade
|
| Cash Acquisitions | - | - | -75.03 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -12.5 | -2.5 | -30 | - | - | - | Upgrade
|
| Investment in Securities | -204 | 219.82 | -69.66 | -121.34 | -129.66 | 11.79 | Upgrade
|
| Other Investing Activities | -2.58 | -5.05 | -0.84 | -0.94 | -5.56 | - | Upgrade
|
| Investing Cash Flow | -227.52 | 168 | -291.65 | -195.37 | -179.12 | -13.04 | Upgrade
|
| Issuance of Common Stock | 719.67 | 388.17 | 10.81 | 119.04 | 600.51 | 365.07 | Upgrade
|
| Other Financing Activities | 7 | -0.03 | 490.4 | -0.49 | -0.24 | 314.23 | Upgrade
|
| Financing Cash Flow | 726.67 | 388.14 | 501.21 | 118.55 | 600.27 | 679.31 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.05 | 0.46 | -1.08 | -1.19 | 1.12 | -0.17 | Upgrade
|
| Net Cash Flow | 81.61 | 81.8 | -171.98 | -416.71 | 290.05 | 320.72 | Upgrade
|
| Free Cash Flow | -427.03 | -519.07 | -496.59 | -411.79 | -176.13 | -370.22 | Upgrade
|
| Free Cash Flow Margin | -81.69% | -119.53% | -136.68% | -117.18% | -64.98% | -356.96% | Upgrade
|
| Free Cash Flow Per Share | -4.91 | -7.06 | -7.10 | -6.07 | -2.89 | -6.54 | Upgrade
|
| Levered Free Cash Flow | -231.16 | -312.22 | -370.59 | -244.82 | -86.45 | -211.9 | Upgrade
|
| Unlevered Free Cash Flow | -190.63 | -270.97 | -343.71 | -226.43 | -65.65 | -211.19 | Upgrade
|
| Change in Net Working Capital | 21.13 | 29.67 | -59.4 | 32.97 | -86.58 | 11.78 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.